Trial Profile
Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab emtansine (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Carcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms TEAL
- 12 Apr 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2018 Status changed from completed to active, no longer recruiting.
- 23 Jul 2018 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.